DUSA Pharmaceuticals (DUSA)
DUSA Pharmaceuticals Receivables Turnover: 16.83
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
DUSA Receivables Turnover Rankings
| Overall | 84th percentile | 543 of 3458 |
| Sector | 88th percentile | 46 of 391 in Healthcare |
| Industry | 78th percentile | 6 of 28 in Drug Manufacturers - Other |
DUSA Receivables Turnover Range, Past 5 Years
| Minimum | 11.48 | Dec 2008 |
| Maximum | 16.83 | Mar 2012 |
| Average | 13.67 |
About Receivables Turnover Ratio
The receivable turnover ratio quantifies a company's ability to collect liabilities/debts. It helps investors gauge the efficiency of a company's collection and credit policies.
A high ratio value indicates an efficient and effective credit policy, and a low ratio indicates a debt collection problem.
The way to read the receivables turnover ratio is as follows. Assume that a company has a receivables turnover ratio of 10. We say that "the company turns over its receivables 10 times during the year." In other words, on average the company collects its outstanding receivables 10 times per year.
Learn More
You may also be interested in these DUSA related companies
DUSA News
$DUSA - Initial Stop hit. Trade close @ Initial Stop of $5.10 - http://stks.co/3so5
about 12 days ago by TraderFoxxx
about 12 days ago by TraderFoxxx
$DUSA forms bearish "Diamond Top" chart pattern. http://stks.co/3mUY
about 18 days ago by RecogniaEvents
about 18 days ago by RecogniaEvents
Listen to $DUSA Q1 2012 earnings call - live at 08:30 AM, ondemand after - http://stks.co/3iR7
about 21 days ago by earningscast
about 21 days ago by earningscast
DUSA Pharmaceuticals Reports First Quarter 2012 Corporate Highlights and Financial Results
May 08, 6:30AM GlobeNewswire
May 08, 6:30AM GlobeNewswire
DUSA Pharmaceuticals Completes Enrollment in Phase 2 Studies of Levulan(R) Kerastick(R) Photodynamic Therapy
Apr 24, 7:30AM GlobeNewswire
Apr 24, 7:30AM GlobeNewswire
DUSA Pharmaceuticals Introduces Teeing Off Against Sun Damage(TM) Campaign to Raise Awareness of Actinic Keratosis
Apr 10, 8:30AM GlobeNewswire
Apr 10, 8:30AM GlobeNewswire
Trade Signal-New $DUSA -BTO @ 6.48-Limit w/5.10-Stop on the Wkly Chart w/.5N @ Risk http://chart.ly/t5llhwx
about 64 days ago by TraderFoxxx
about 64 days ago by TraderFoxxx
DUSA Pharmaceuticals to Present at the 2012 Maxim Group Growth Conference
Mar 23, 8:00AM GlobeNewswire
Mar 23, 8:00AM GlobeNewswire
$DUSA http://stks.co/2wc5 broke over lower range on volume of 150% of full day average - has a level overhead
about 71 days ago by StockTiger
about 71 days ago by StockTiger
DUSA Pharmaceuticals to Present at the 2012 Maxim Group Growth Conference
Mar 19, 8:30AM GlobeNewswire
Mar 19, 8:30AM GlobeNewswire
DUSA Pharmaceuticals to Present at Roth Capital Partners 24th Annual OC Growth Stock Conference
Mar 07, 8:30AM GlobeNewswire
Mar 07, 8:30AM GlobeNewswire
Listen to $DUSA Q4 2011 earnings call - live at 08:30 AM, ondemand after - http://stks.co/2giF
about 84 days ago by earningscast
about 84 days ago by earningscast
DUSA Pharmaceuticals Reports Full Year 2011 Corporate Highlights and Financial Results
Mar 06, 6:30AM GlobeNewswire
Mar 06, 6:30AM GlobeNewswire
DUSA Pharmaceuticals to Present at the Leerink Swann 2012 Global Healthcare Conference
Feb 08, 8:30AM GlobeNewswire
Feb 08, 8:30AM GlobeNewswire
DUSA Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference
Feb 06, 9:10AM GlobeNewswire
Feb 06, 9:10AM GlobeNewswire
DUSA Pharmaceuticals, Inc. (DUSA) CEO to Ring The NASDAQ Stock Market Opening Bell
Dec 21, 12:20PM GlobeNewswire
Dec 21, 12:20PM GlobeNewswire
DUSA Pharmaceuticals Reports Third Quarter 2011 Corporate Highlights and Financial Results
Nov 10, 6:30AM GlobeNewswire
Nov 10, 6:30AM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| DUSA | 5.44 | +0.04 | +0.74% | 134.10M |
| DUK | 21.96 | +0.16 | +0.73% | 29.38B |
| DUG | 27.46 | +0.20 | +0.73% | |
| DUF | 14.83 | -0.07 | -0.47% | 515.79M |
| DUCK | 8.11 | +0.09 | +1.12% | 31.14M |
| DUC | 12.40 | +0.06 | +0.49% | |
| DTV | 46.40 | +0.03 | +0.06% | 31.39B |
| DRH | 9.85 | -0.01 | -0.10% | 1.661B |
| DRE | 13.72 | -0.07 | -0.51% | 3.569B |
| DRD | 6.24 | +0.06 | +0.97% | 240.18M |